Global Pulmonary Surfactant Market to Surpass US$ 822.9 Million by 2030, Says Coherent Market Insights (CMI)
Burlingame, Jan. 05, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global *pulmonary surfactant** market* is estimated to be valued at *US**$ 578.7 million* in *2022* and is expected to exhibit a *CAGR* of *4.50**%* during the forecast period *(2022-2030).**Key Trends and Analysis of the Global **Pulmonary Surfactant** Market: *
Major players operating in market are focusing on adopting growth strategies such as scientific advancement and patent claim, which is expected to drive the global pulmonary surfactant market growth over the forecast period. For instance, in April 2021, Windtree Therapeutics, Inc., a biotechnology and medical device company multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO) for a patent stemming from an application it filed previously under the Patent Cooperation Treaty (PCT). Under this USPTO program, the new istaroxime patent is expected to receive examination and final disposition within one year of priority status being granted, rather than the customary three years of examination anticipated by the USPTO for non-prioritized examinations. Windtree took this step to strengthen the istaroxime patent estate.
Moreover, in October 2021, Windtree Therapeutics, Inc., a biotechnology and medical device company multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of new patent claims for istaroxime administration. A notice of allowance is issued by the USPTO to indicate that the application has passed examination. When the patent is issued by the USPTO in the near future, it will provide new intellectual property protection for istaroxime until late 2039.
*Request Sample copy of this Report @ **https://www.coherentmarketinsights.com/insight/request-sample/5324*
*Key Market Takeaways:*
Market players are focused on growth strategies such as signing distribution and agreements owing to the increasinge pulmonary surfactant market. For instance, in December 2021, Aerogen Pharma, pharmaceutical company, and Nuance Pharma, a biopharma with late‐stage clinical programs company, announce an exclusive agreement to join forces in Greater China to develop a superior, non‐invasive approach to treatment of RDS, respiratory distress syndrome, a life‐threatening condition of preterm infants associated with long‐term lung health issues in survivors.
Among type, animal derived surfactant segment generated significant revenue in 2022, owing to increasing incidence of respiratory diseases worldwide. For instance, on May 3, 2022, a report was published in Frontiers Media, a publisher of peer-reviewed open access scientific journals currently, which reported that the pulmonary surfactant mitigate and reverse ARDS, Acute respiratory distress syndrome, by reducing alveolar surface tension and improving pulmonary mechanical properties, while also exerting anti-inflammatory and antiviral effects. The application of pulmonary surfactant provide an effective strategy for the treatment of respiratory diseases.
Among region, North America is expected to hold a dominant position in the global *pulmonary surfactant* market over the forecast period, owing to increasing prevalence of chronic lung disease in region. For instance, in February 2021, according to the reports published in National Center for Biotechnology Information, stated about Prevalence and clinical characteristics of perinatal chronic lung disease by infant gestational age in the U.S. which resulted as higher number of infected infants were reported during the study. Approximately 300 infants born at >32 wGA (weeks’ gestational age) are diagnosed with CLD (Chronic Liver Disease), Perinatal chronic lung disease, annually in the U.S.
*Competitive Landscape:*
Key players operating in the global pulmonary surfactant market include Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech.
*Buy-Now this Research Report @ **https://www.coherentmarketinsights.com/insight/buy-now/5324*
*Market Segmentation:*
· *Global Pulmonary Surfactant Market, By Type*
· Synthetic Pulmonary Surfactant
· Animal Derived Surfactant
· *Global Pulmonary Surfactant Market, By Drug Type*
· Poractant alfa
· Lucinactant
· Calfactant
· *Global Pulmonary Surfactant Market, By Indications*
· Global Pulmonary Surfactant Market
· Respiratory Infections
· Obstructive lung Diseases
· Others (chronic lung disease of prematurity, and surfactant protein-B deficiency)
· *Global Pulmonary Surfactant Market, By Route of Administration*
· Intratracheal
· Injectable
· *Global Pulmonary Surfactant Market, By Distribution Channel*
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
· *Global Pulmonary Surfactant Market, By Region:*
· North America
· By Country:
· U.S.
· Canada
· Latin America
· By Country:
· Brazil
· Mexico
· Argentina
· Rest of Latin America
· Europe
· By Country:
· U.K.
· Germany
· Italy
· Spain
· France
· Russia
· Rest of Europe
· Asia Pacific
· By Country:
· Australia
· India
· China
· Japan
· ASEAN
· South Korea
· Rest of Asia Pacific
· Middle East
· By Country:
· GCC
· Israel
· Rest of Middle East
· Africa
· By Country/Region:
· South Africa
· Central Africa
· North Africa
*Related Market Intelligence Reports:*
*Pulmonary Drug Delivery Systems Market*, By Product Type (Nebulizers, MDIs, DPIs), By Application (Asthma, COPD, Cystic Fibrosis), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
*Pulmonary Arterial Hypertension Drug Market*, by Drug Class (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, Others), by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
*About Us:*
*Coherent Market Insights* is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
*Follow Us: **LinkedIn** | **Twitter*
CONTACT: Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com